ForPatients
by Roche

Alzheimer's Disease (AD)

A study comparing different tools for looking at the brain in people with Alzheimer’s disease: tau radiotracers for brain imaging with Positron Emission Tomography (PET)

Evaluation Comparing Two Tau PET Radiotracers, [18F]PI-2620 and [18F]GTP1, in Brains of Participants With Prodromal or Mild Alzheimer's Disease

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT04566003 GN42801

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study aimed to better understand Alzheimer's disease and improve ways to find tau protein in the brain. People over 65 with normal brain function and those over 50 with Alzheimer's could join. Participants took memory and thinking tests, had health checks, including brain MRIs, and most importantly, had PET scans with three different radiotracers. These scans helped compare the radiotracers' effectiveness in detecting tau and beta-amyloid deposits. The radiotracers were safe to use. The main benefit was the valuable information gained, helping researchers advance in understanding and detecting Alzheimer's disease.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)	Phase 1
Sponsor	Phase

NCT04566003 GN42801
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=50 Years & <= 90 Years	No